Evidence map›Paper›PMID 31506605›Full record

ArticleOncogene2020

Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling.

Jinbo Chen, Fuju Chou, Shuyuan Yeh, Zhenyu Ou, Chihrong Shyr, Chiping Huang, Zhendong Xiang, Yin Sun, Edward Messing, Xiongbing Zu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. The androgen receptor in bladder cancer.Nature reviews. Urology · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Jinbo ChenDepartments of Urology, Xiangya Hospital, Central South University, 410008, Changsha, China.
Fuju ChouGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Institute, Rochester, NY, USA.
Shuyuan YehGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Institute, Rochester, NY, USA.
Zhenyu OuDepartments of Urology, Xiangya Hospital, Central South University, 410008, Changsha, China.
Chihrong ShyrSex Hormone Research Center, Departments of Urology and Medical Technology, China Medical University/Hospital, 404, Taichung, Taiwan.
Chiping HuangSex Hormone Research Center, Departments of Urology and Medical Technology, China Medical University/Hospital, 404, Taichung, Taiwan.
Zhendong XiangGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Institute, Rochester, NY, USA.
Yin SunGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Institute, Rochester, NY, USA.
Edward MessingGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Institute, Rochester, NY, USA.
Xiongbing ZuDepartments of Urology, Xiangya Hospital, Central South University, 410008, Changsha, China. whzuxb@163.com.
Chawnshang ChangGeorge Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Institute, Rochester, NY, USA. chang@urmc.rochester.edu.
University of Rochester Medical Center · USCentral South University · CNChina Medical University · TWChina Medical University Hospital · TWXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While androgens may function via nuclear androgen receptor (nAR) to increase bladder cancer (BCa) progression, the impact of androgens on muscle invasive BCa, which contains nearly 80% nAR-negative cells, remains unclear. To dissect the androgens potential impacts on these nAR-negative muscle invasive BCa, we first found that the androgens, dihydrotestosterone (DHT) might function via a novel membrane AR (mAR-SLC39A9) to increase nAR-negative BCa cell migration and invasion. Mechanism dissection revealed that DHT/mAR-SLC39A9 might function by altering G

Indexed as

Androgen AntagonistsAnimalsCation Transport ProteinsCell Line, TumorCell MembraneCell MovementCystectomyDatasets as TopicDihydrotestosteroneDisease ProgressionFemaleGTP-Binding Protein alpha Subunits, Gi-GoHumansIndazolesMaleMAP Kinase Signaling SystemAndrogen AntagonistsCation Transport ProteinsDihydrotestosteroneGTP-Binding Protein alpha Subunits, Gi-GoIndazolesMatrix Metalloproteinase 9MMP9 protein, humanPertussis ToxinPiperazinesRNA, Small InterferingSCH772984Slc39a9 protein, human

Identifiers

PMID31506605
OpenAlexW2972884112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.